INDICATIONS AND USAGE. IYUZEH™ (latanoprost ophthalmic solution) 0.005% is a prostaglandin F2α analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

INDICATIONS AND USAGE. IYUZEH™ (latanoprost ophthalmic solution) 0.005% is a prostaglandin F2α analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Thea’s Commitment to Access and Affordability. Thea Pharma Inc. is committed to helping patients get access to their medications. Thea’s Patient Assistance Program is intended for US patients that have a demonstrated financial need and are without prescription insurance coverage.

Patients treated with either IYUZEH or XALATAN ® provided clinically meaningful reductions in IOP from baseline to all follow-up visits and time points (n=335). At day 84, the mean ± SD diurnal IOP was 16.3±2.5 mmHg in the IYUZEH group and 15.7±2.6 mmHg in the XALATAN group, representing percentage IOP decreases of 13.8% and 17.7%, respectively.

3 INDICATION FREQUENTLY ASKED QUESTIONS Q. What is the indication for IYUZEH™? A. IYUZEH (latanoprost ophthalmic solution) 0.005% is a prostaglandin F2α analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle

E-Prescribe via EMR Pharmacy Name: PhilRx, LLC, Columbus, OH Type: Retail | NPI: 1487463598 Prefer to fax in prescriptions? Fax at (888) 975-0603 *PhilRx is a third-party vendor that administers our patient support program.

In randomized, controlled clinical trials of patients with mean baseline IOP as low as 19 and as high as 24 mmHg,* IYUZEH™ (latanoprost ophthalmic solution) 0.005% showed proven efficacy through clinically meaningful IOP reductions. 1-3

In clinical trials conducted with IYUZEH™ (latanoprost ophthalmic solution) 0.005% comparing it to XALATAN ®, the most frequently reported ocular adverse reactions were conjunctival hyperemia (34% for IYUZEH vs 37% for XALATAN) and eye irritation (19% for IYUZEH vs 31% for XALATAN). 1,2

The proportion of patients satisfied with preservative-free latanoprost ophthalmic solution 0.005% was similar among patients who had previously received preserved medication 95.3% (p<0.0001) and among those who were treatment-naive (97.3%). 1*Based on results from a multicenter, international, transverse, epidemiological survey conducted in routine private ophthalmology …

INDICATIONS AND USAGE. IYUZEH™ (latanoprost ophthalmic solution) 0.005% is a prostaglandin F2α analogue indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.